Rheumatology:甲襞视频毛细管镜检查是评估ANCA相关性血管炎的有用工具

2022-07-20 紫菀款冬 MedSci原创

评价甲襞视频毛细血管技术(NVC)作为评估抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)疾病活动性的有用工具。

目的:评价甲襞视频毛细血管技术(NVC)作为评估抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)疾病活动性的有用工具。

方法:该研究纳入51例AAV患者和21名健康对照者。对NVC结果进行半定量评分,并在AAV患者和对照组之间进行比较。研究了NVC发现与AAV中疾病活动指标皮肤活检的组织病理学发现和高分辨率计算机断层扫描(HRCT)评分的相关性。此外,在免疫抑制治疗3个月后,重复评估NVC结果 。

结果:70.6%(36/51)表现为微血管病变,7.8%(4/51)表现为硬皮病。AAV组的微出血、毛细血管丢失、新生血管生成和迂曲评分显著高于对照组。NVC异常与皮肤、肺和肾脏受累的严重程度相关巨大毛细血管评分与总血管炎活动度评分(BVAS)和胸部BVAS显著相关毛细血管损失评分与胸部BVAS和肾脏BVAS相关

微出血评分与紫癜上部真皮血管周围炎性细胞浸润显著相关,并且倾向于与HRCT上的毛玻璃样总混浊和实变评分相关。此外,毛细血管损失评分与血清肌酐水平显著正相关。免疫抑制治疗3个月后,微出血评分显著降低。

结论:在AAV患者中,NVC异常与疾病严重程度显著相关。这一结果表明,NVC是评估AAV疾病活动和治疗反应的有用工具

 

文献来源:

Matsuda S, Kotani T, Wakura R, et al. Examination of nailfold videocapillaroscopy findings in ANCA-associated vasculitis [published online ahead of print, 2022 Jul 11]. Rheumatology (Oxford). 2022;keac402. doi:10.1093/rheumatology/keac402

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1838089, encodeId=723d183808921, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Apr 22 12:04:09 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062590, encodeId=e03d2062590ce, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue Aug 02 16:04:09 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233596, encodeId=ee4d12335967f, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 20 12:42:00 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233592, encodeId=180212335928d, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ca05469727, createdName=小夜夜, createdTime=Wed Jul 20 12:18:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263278, encodeId=fd0612632e84d, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sat Jul 16 09:04:09 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400824, encodeId=e3f31400824f7, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EE600EF84628E8BB8DF2285885814D26/100, createdBy=116f2265509, createdName=Boyinsh, createdTime=Sat Jul 16 09:04:09 CST 2022, time=2022-07-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1838089, encodeId=723d183808921, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Apr 22 12:04:09 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062590, encodeId=e03d2062590ce, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue Aug 02 16:04:09 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233596, encodeId=ee4d12335967f, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 20 12:42:00 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233592, encodeId=180212335928d, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ca05469727, createdName=小夜夜, createdTime=Wed Jul 20 12:18:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263278, encodeId=fd0612632e84d, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sat Jul 16 09:04:09 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400824, encodeId=e3f31400824f7, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EE600EF84628E8BB8DF2285885814D26/100, createdBy=116f2265509, createdName=Boyinsh, createdTime=Sat Jul 16 09:04:09 CST 2022, time=2022-07-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1838089, encodeId=723d183808921, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Apr 22 12:04:09 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062590, encodeId=e03d2062590ce, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue Aug 02 16:04:09 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233596, encodeId=ee4d12335967f, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 20 12:42:00 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233592, encodeId=180212335928d, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ca05469727, createdName=小夜夜, createdTime=Wed Jul 20 12:18:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263278, encodeId=fd0612632e84d, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sat Jul 16 09:04:09 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400824, encodeId=e3f31400824f7, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EE600EF84628E8BB8DF2285885814D26/100, createdBy=116f2265509, createdName=Boyinsh, createdTime=Sat Jul 16 09:04:09 CST 2022, time=2022-07-16, status=1, ipAttribution=)]
    2022-07-20 yangchou

    好文章,谢谢分享。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1838089, encodeId=723d183808921, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Apr 22 12:04:09 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062590, encodeId=e03d2062590ce, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue Aug 02 16:04:09 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233596, encodeId=ee4d12335967f, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 20 12:42:00 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233592, encodeId=180212335928d, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ca05469727, createdName=小夜夜, createdTime=Wed Jul 20 12:18:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263278, encodeId=fd0612632e84d, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sat Jul 16 09:04:09 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400824, encodeId=e3f31400824f7, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EE600EF84628E8BB8DF2285885814D26/100, createdBy=116f2265509, createdName=Boyinsh, createdTime=Sat Jul 16 09:04:09 CST 2022, time=2022-07-16, status=1, ipAttribution=)]
    2022-07-20 小夜夜

    非常好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1838089, encodeId=723d183808921, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Apr 22 12:04:09 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062590, encodeId=e03d2062590ce, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue Aug 02 16:04:09 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233596, encodeId=ee4d12335967f, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 20 12:42:00 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233592, encodeId=180212335928d, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ca05469727, createdName=小夜夜, createdTime=Wed Jul 20 12:18:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263278, encodeId=fd0612632e84d, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sat Jul 16 09:04:09 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400824, encodeId=e3f31400824f7, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EE600EF84628E8BB8DF2285885814D26/100, createdBy=116f2265509, createdName=Boyinsh, createdTime=Sat Jul 16 09:04:09 CST 2022, time=2022-07-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1838089, encodeId=723d183808921, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Apr 22 12:04:09 CST 2023, time=2023-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062590, encodeId=e03d2062590ce, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue Aug 02 16:04:09 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233596, encodeId=ee4d12335967f, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Wed Jul 20 12:42:00 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233592, encodeId=180212335928d, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ca05469727, createdName=小夜夜, createdTime=Wed Jul 20 12:18:54 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263278, encodeId=fd0612632e84d, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Sat Jul 16 09:04:09 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400824, encodeId=e3f31400824f7, content=<a href='/topic/show?id=0ba9248543' target=_blank style='color:#2F92EE;'>#ANCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2485, encryptionId=0ba9248543, topicName=ANCA)], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EE600EF84628E8BB8DF2285885814D26/100, createdBy=116f2265509, createdName=Boyinsh, createdTime=Sat Jul 16 09:04:09 CST 2022, time=2022-07-16, status=1, ipAttribution=)]
    2022-07-16 Boyinsh

相关资讯

J Rheumatol:ANCA相关性血管炎患者主要感染的患病率和危险因素

这项研究结果证实,主要感染是AAV患者死亡的主要原因。

风湿免疫科ANCA指标解读,别看它“冷门”,却很有价值

不容错过的风湿免疫科指标解读:ANCA阳性的临床意义。

BMJ:血浆置换对ANCA相关性血管炎患者的影响

对于AAV的治疗,血浆置换对患者死亡率没有显著影响,其降低了12个月的ESKD风险,但增加了严重感染的风险。

Arthritis Rheumatol:ANCA相关性血管炎的疾病活动性、ANCA类型和脂质水平

在新诊断和PR3-ANCA+的AAV患者中,缓解诱导期间的脂质水平升高。

J Rheumatol:ANCA相关性血管炎相关的支气管扩张谱系与预后

支气管扩张与AAV的关联并非偶然,主要与MPO-ANCA相关。支气管扩张早于AAV发作的患者往往具有独特的临床和生物学特征,并且预后更差。

FDA授予Avacopan治疗ANCA相关性血管炎的新药申请(NDA)

抗中性粒细胞胞质抗体(ANCA)相关性血管炎(AAV)是一类以小血管坏死性炎症和ANCA存在为特征的自身免疫性疾病,可以累及全身多系统,严重时可威胁生命,治疗后容易复发。